Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Liabilities and Shareholders Equity: 2010-2024

Historic Liabilities and Shareholders Equity for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Dec 2024 value amounting to $350.9 million.

  • Ironwood Pharmaceuticals' Liabilities and Shareholders Equity rose 1.68% to $396.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 16.40%. This contributed to the annual value of $350.9 million for FY2024, which is 25.51% down from last year.
  • As of FY2024, Ironwood Pharmaceuticals' Liabilities and Shareholders Equity stood at $350.9 million, which was down 25.51% from $471.1 million recorded in FY2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Liabilities and Shareholders Equity peaked at $1.1 billion during FY2021, and registered a low of $350.9 million during FY2024.
  • For the 3-year period, Ironwood Pharmaceuticals' Liabilities and Shareholders Equity averaged around $640.8 million, with its median value being $471.1 million (2023).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 101.51% in 2021, then crashed by 57.20% in 2023.
  • Yearly analysis of 5 years shows Ironwood Pharmaceuticals' Liabilities and Shareholders Equity stood at $559.2 million in 2020, then spiked by 101.51% to $1.1 billion in 2021, then dropped by 2.34% to $1.1 billion in 2022, then slumped by 57.20% to $471.1 million in 2023, then decreased by 25.51% to $350.9 million in 2024.